Fast Five Quiz: Melanoma Treatment

Chih-Shan Jason Chen, MD, PhD


January 24, 2020

Results from the second Multicenter Selective Lymphadenectomy Trial, which were published in 2017, confirmed that immediate CLND in patients with metastases found on SLNB increases the rate of regional disease control and provides prognostic information. However, no increase in melanoma-specific survival after immediate CLND were noted.

In that same trial, CLND increased the risk for lymphedema, occurring in 24.1% of the dissection group versus 6.3% of the observation group (P < .001). However, in the majority of cases (64%), lymphedema was mild, whereas it was moderate in 33% of cases and severe in 3%.

Learn more about regional lymph node dissection in patients with melanoma.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.